A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity

Functional tumor-specific cytotoxic T cells elicited by therapeutic cancer vaccination in combination with oncolytic viruses offer opportunities to address resistance to checkpoint blockade therapy. Two cancer vaccines, the self-adjuvanting protein vaccine KISIMA, and the recombinant oncolytic vesic...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Krishna, Belnoue, Elodie, Rossi, Matteo, Hofer, Tamara, Danklmaier, Sarah, Nolden, Tobias, Schreiber, Liesa-Marie, Angerer, Katharina, Kimpel, Janine, Hoegler, Sandra, Spiesschaert, Bart, Kenner, Lukas, von Laer, Dorothee, Elbers, Knut, Derouazi, Madiha, Wollmann, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408233/
https://www.ncbi.nlm.nih.gov/pubmed/34465781
http://dx.doi.org/10.1038/s41467-021-25506-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408233/
https://www.ncbi.nlm.nih.gov/pubmed/34465781
http://dx.doi.org/10.1038/s41467-021-25506-6

Ejemplares similares